Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + losartan
- Development stage
- Unknown
- Lead developer
- Tehran University of Medical Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intravitreal, Oral
01
Overview
Bevacizumab + losartan is a combination therapy consisting of the monoclonal antibody bevacizumab and the angiotensin II receptor blocker (ARB) losartan. Bevacizumab inhibits vascular endothelial growth factor A (VEGF-A), thereby reducing angiogenesis and vascular permeability, while losartan blocks the angiotensin II type 1 receptor, leading to vasodilation and reduced extracellular matrix remodeling. This combination has been investigated as an adjunctive treatment in conditions such as diabetic macular edema (DME), where oral losartan is used alongside intravitreal injections of bevacizumab to potentially enhance therapeutic outcomes. Additionally, preclinical studies have explored this combination for improving drug delivery and immune responses in tuberculosis lung lesions[1][2][4][6].
- Other names
- bevacizumab and losartanbevacizumab plus losartan
02
Targets
VEGFA (Vascular endothelial growth factor A)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on bevacizumab + losartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + losartan.